Previous 10 |
home / stock / hltrf / hltrf news
Health Canada grants priority review status for Amarin's (NASDAQ: AMRN ) licensee, HLS Therapeutics' ( OTCPK:HLTRF ) New Drug Submission (“NDS”) for Vascepa (icosapent ethyl) capsules. More news on: Amarin Corporation plc, HLS Therapeutics Inc., Healthcare stocks news, ...
HLS Therapeutics ( OTCPK:HLTRF ): Q4 GAAP EPS of $0.01. More news on: HLS Therapeutics Inc., Earnings news and commentary, Tech stocks news, Read more ...
HLS Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference Canada NewsWire TORONTO, Feb. 19, 2019 TORONTO , Feb. 19, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on cent...
News, Short Squeeze, Breakout and More Instantly...
HLS Therapeutics Inc Company Name:
HLTRF Stock Symbol:
OTCMKTS Market:
HLS Therapeutics Inc Website:
HLS Therapeutics Announces First Quarter Fiscal 2021 Financial Results Canada NewsWire Q1 2021 revenue of $14.3 million , Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million , up $0.4 million , $0.6 million and $1.8 million ...
HLS Therapeutics to Host Q1 2021 Financial Results Conference Call Canada NewsWire TORONTO , April 22, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021 ...
HLS Therapeutics Announces Participation in Upcoming Conferences Canada NewsWire TORONTO , April 15, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular ma...